CVS Health Corporation $CVS Stock Holdings Increased by Krilogy Financial LLC

Posted by George Bondi on Oct 16th, 2026

Krilogy Financial LLC increased its stake in shares of CVS Health Corporation (NYSE:CVS – Free Report) by 49.6% in the 3rd quarter, according to its most recent 13F filing with the SEC. The firm owned 19,343 shares of the pharmacy operator’s stock after buying an additional 6,411 shares during the period. Krilogy Financial LLC’s holdings in CVS Health were worth $1,658,000 as of its most recent filing with the SEC.

Other hedge funds and other institutional investors have also modified their holdings of the company. Handelsbanken Fonder AB grew its position in shares of CVS Health by 83.6% during the 2nd quarter. Handelsbanken Fonder AB now owns 1,089,694 shares of the pharmacy operator’s stock worth $112,729,000 after purchasing an additional 496,124 shares in the last quarter. BNP Paribas raised its position in shares of CVS Health by 105.2% in the second quarter. BNP Paribas now owns 49,971 shares of the pharmacy operator’s stock valued at $5,154,000 after buying an additional 25,617 shares in the last quarter. Nykredit A S acquired a new stake in shares of CVS Health in the second quarter valued at approximately $209,813,000. Oppenheimer Asset Management Inc. bought a new stake in shares of CVS Health in the second quarter valued at approximately $49,622,000. Finally, Bank of America Corp DE boosted its stake in shares of CVS Health by 148.0% in the second quarter. Bank of America Corp DE now owns 23,188,670 shares of the pharmacy operator’s stock valued at $2,398,868,000 after buying an additional 13,836,701 shares during the period. Institutional investors own 80.66% of the company’s stock.

CVS Health Stock Up 2.3%

NYSE CVS opened at $92.45 on Friday. The business has a fifty day moving average price of $91.80 and a two-hundred day moving average price of $93.03. The stock has a market capitalization of $118.25 billion, a PE ratio of 24.46, a PEG ratio of 0.84 and a beta of 0.60. CVS Health Corporation has a fifty-two week low of $69.51 and a fifty-two week high of $110.68. The company has a debt-to-equity ratio of 0.74, a current ratio of 0.87 and a quick ratio of 0.66.

CVS Health (NYSE:CVS – Get Free Report) last issued its quarterly earnings results on Wednesday, August 5th. The pharmacy operator reported $2.58 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.87 by $0.71. CVS Health had a return on equity of 13.12% and a net margin of 1.18%. The company had revenue of $106.10 billion for the quarter, compared to analyst estimates of $100.03 billion. During the same quarter last year, the company posted $1.81 EPS. The company’s revenue for the quarter was up 7.3% compared to the same quarter last year. CVS Health has set its FY 2026 guidance at 7.900-8.100 EPS. Equities analysts expect that CVS Health Corporation will post 8.02 earnings per share for the current fiscal year.

CVS Health Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Monday, November 2nd. Investors of record on Thursday, October 22nd will be paid a $0.6650 dividend. The ex-dividend date of this dividend is Thursday, October 22nd. This represents a $2.66 annualized dividend and a yield of 2.9%. CVS Health’s dividend payout ratio (DPR) is 70.37%.

Wall Street Analyst Weigh In

A number of equities research analysts recently issued reports on CVS shares. Piper Sandler set a $112.00 price target on CVS Health in a research report on Wednesday, September 9th. UBS Group reaffirmed a “buy” rating on shares of CVS Health in a report on Tuesday, September 22nd. Wells Fargo & Company upped their target price on CVS Health from $103.00 to $123.00 and gave the company an “overweight” rating in a research report on Monday, July 13th. Barclays upped their target price on CVS Health from $106.00 to $108.00 and gave the company an “overweight” rating in a research report on Thursday, August 6th. Finally, Leerink Partners decreased their price target on CVS Health from $119.00 to $112.00 and set an “outperform” rating on the stock in a research report on Monday. Twenty equities research analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the stock. Based on data from MarketBeat, CVS Health has an average rating of “Moderate Buy” and a consensus target price of $107.80.

View Our Latest Report on CVS Health

CVS Health News Summary

Here are the key news stories impacting CVS Health this week:

Positive Sentiment: Improving fundamentals and valuation support the stock. CVS has recently exceeded earnings and revenue expectations, while analysts cited stronger returns, rising earnings estimates and a lower valuation than Alignment Healthcare. Its Aetna turnaround is also viewed as a potential catalyst. CVS vs. ALHC: Which Medicare Advantage Stock Is the Better Pick Now?
Positive Sentiment: Expanded care access and quality credentials reinforce CVS’s healthcare-services strategy. CVS opened its first pharmacy-focused location in the Boston area to improve access to medications, immunizations and other services. Separately, MinuteClinic received its seventh consecutive Joint Commission accreditation, with primary care available at more than 65% of its locations. CVS Pharmacy Celebrates Opening of First Pharmacy-Focused Location in Boston Area
Neutral Sentiment: New women’s-health collaboration could support longer-term engagement. CVS is partnering with The Midlife Collective on a research study and documentary focused on women’s midlife health. The initiative may strengthen brand awareness and consumer relationships, but it is unlikely to have a near-term financial impact. CVS Health Collaborates With The Midlife Collective
Positive Sentiment: Home-based heart monitoring expands value-added services. Signify Health, part of CVS, offers continuous heart-rhythm monitoring for eligible health-plan members, potentially enabling earlier detection of serious conditions and supporting preventive-care economics. CVS Health: Early Detection Matters
Negative Sentiment: $315 million opioid settlement creates legal, financial and reputational pressure. CVS agreed to settle Justice Department allegations involving unlawful opioid dispensing and false claims. The company admitted no wrongdoing but will implement tighter controlled-substance oversight, adding costs and highlighting compliance risks. CVS Agrees to Pay $315M

CVS Health Company Profile

(Free Report)

CVS Health Corp. is an integrated health care company that provides pharmacy, insurance and health services primarily in the United States. Its operations are designed to connect consumers, health plans, health care providers and pharmacy services across multiple points of care.

The company’s major businesses include CVS Pharmacy retail locations, prescription fulfillment and consumer health products; CVS Caremark, a pharmacy benefit management business; and Aetna, which offers health insurance products and related services for employers, individuals, government programs and other organizations.